Antifolate resistance markers and complexity of infection in children with sickle cell anaemia receiving malaria chemoprevention in Uganda: a molecular sub-study of the CHEMCHA randomised trial

Background Sickle cell anaemia (SCA) is a major public health problem in Uganda. Monthly sulfadoxine-pyrimethamine (SP) remains the standard malaria chemoprevention regimen despite widespread antifolate resistance in East Africa. We assessed Pfdhfr and Pfdhps resistance mutations and the complexity of infection (COI) among children with SCA receiving malaria chemoprevention. Methods This prospective study of antifolate resistance was nested within the CHEMCHA randomised controlled trial comparing monthly SP with weekly dihydroartemisinin-piperaquine (DP) for malaria chemoprevention. Participants were children with SCA aged 6 months to 15 years and attending Jinja and Kitgum hospitals in Uganda. Dried blood spots were collected at enrolment, study closeout, and during febrile episodes. Parasite DNA from microscopy-confirmed clinical malaria samples was genotyped by amplicon sequencing for Pfdhfr (N51I, C59R, S108N, and I164L) and Pfdhps (A437G, K540E, A581G, A613S, and A613T). COI was estimated using MOIRE. Results Complete Pfdhfr/Pfdhps haplotypes were resolved for 7-28 isolates per site and time point, and COI was estimated for 67 samples. The quintuple mutant (Pfdhfr IRN/Pfdhps GE) accounted for 85.7-100% of isolates across sites and time points; A613S and A613T were not detected. Pfdhfr I164L was detected in 2/9 isolates in Jinja at baseline and 1/8 at endline. The Pfdhps A581G mutant allele was absent at baseline (0/44 isolates) but was found in 1/8 isolates in Jinja and 3/34 in Kitgum at endline, including quintuple-plus-581G (sextuple) haplotypes in 1/8 and 2/27 isolates, respectively. Most infections were monoclonal (51/67, 76.1%). Conclusions The high prevalence of quintuple antifolate-resistant haplotypes and the detection of higher-level resistance markers, including emerging sextuple mutants carrying Pfdhfr I164L and Pfdhps A581G, call into question the continued use of SP for chemoprevention in children with SCA in Uganda and support evaluation of alternative regimens.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.08.26367568
Primary Topic
Malaria Research and Control
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Antifolate resistance markers and complexity of infection in children with sickle cell anaemia receiving malaria chemoprevention in Uganda: a molecular sub-study of the CHEMCHA randomised trial

Thomas Katairo, Erick Jacob Okek, Dennis M. Kalibbala, Richard Idro et al.
medRxiv
Malaria Research and Control
preprint

Antifolate resistance markers and complexity of infection in children with sickle cell anaemia receiving malaria chemoprevention in Uganda: a molecular sub-study of the CHEMCHA randomised trial

Thomas Katairo, Erick Jacob Okek, Dennis M. Kalibbala, Richard Idro, Kamija Samuel Phiri, Grace Ndeezi, Winnie Nambatya, Freddie Bwanga, Robert Opika Opoka, John Mbaziira Ssenkusu, Thandile Nkosi-Gondwe, Moses Ocan, Kirikumwino Joanita, Stephen Tukwasibwe, Feiko ter Kuile
preprint en

Abstract

Background Sickle cell anaemia (SCA) is a major public health problem in Uganda. Monthly sulfadoxine-pyrimethamine (SP) remains the standard malaria chemoprevention regimen despite widespread antifolate resistance in East Africa. We assessed Pfdhfr and Pfdhps resistance mutations and the complexity of infection (COI) among children with SCA receiving malaria chemoprevention. Methods This prospective study of antifolate resistance was nested within the CHEMCHA randomised controlled trial comparing monthly SP with weekly dihydroartemisinin-piperaquine (DP) for malaria chemoprevention. Participants were children with SCA aged 6 months to 15 years and attending Jinja and Kitgum hospitals in Uganda. Dried blood spots were collected at enrolment, study closeout, and during febrile episodes. Parasite DNA from microscopy-confirmed clinical malaria samples was genotyped by amplicon sequencing for Pfdhfr (N51I, C59R, S108N, and I164L) and Pfdhps (A437G, K540E, A581G, A613S, and A613T). COI was estimated using MOIRE. Results Complete Pfdhfr/Pfdhps haplotypes were resolved for 7-28 isolates per site and time point, and COI was estimated for 67 samples. The quintuple mutant (Pfdhfr IRN/Pfdhps GE) accounted for 85.7-100% of isolates across sites and time points; A613S and A613T were not detected. Pfdhfr I164L was detected in 2/9 isolates in Jinja at baseline and 1/8 at endline. The Pfdhps A581G mutant allele was absent at baseline (0/44 isolates) but was found in 1/8 isolates in Jinja and 3/34 in Kitgum at endline, including quintuple-plus-581G (sextuple) haplotypes in 1/8 and 2/27 isolates, respectively. Most infections were monoclonal (51/67, 76.1%). Conclusions The high prevalence of quintuple antifolate-resistant haplotypes and the detection of higher-level resistance markers, including emerging sextuple mutants carrying Pfdhfr I164L and Pfdhps A581G, call into question the continued use of SP for chemoprevention in children with SCA in Uganda and support evaluation of alternative regimens.

medRxiv
Liverpool School of Tropical Medicine (GB), Laboratoire National de Référence (MA), National Public Health Laboratory (NP), Kamuzu University of Health Sciences (MW), Makerere University (UG), Uganda Virus Research Institute (UG)
Good health and well-being
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon